Sec Form 4 Filing - Kelsey Stephen Michael @ Revolution Medicines, Inc. - 2020-08-27

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
The following is an SEC EDGAR document rendered as filed.
Here is the list of insider trading transaction codes

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person *
Kelsey Stephen Michael
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
See Remarks
(Last)
(First)
(Middle)
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE
3. Date of Earliest Transaction (MM/DD/YY)
08/27/2020
(Street)
REDWOOD CITY, CA94063
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/27/2020 M( 1 ) 800 A $ 4.09 268,809 D
Common Stock 08/27/2020 S( 1 ) 800 D $ 29.01 ( 2 ) 268,009 D
Common Stock 08/27/2020 S( 1 ) 814 D $ 29.014 ( 2 ) 267,195 D
Common Stock 08/28/2020 M( 1 ) 118 A $ 4.09 267,313 D
Common Stock 08/28/2020 S( 1 ) 118 D $ 29 267,195 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 4.09 08/27/2020 M( 1 ) 800 ( 3 ) 03/12/2029 Common Stock 800 $ 0 107,501 D
Stock Option (Right to Buy) $ 4.09 08/28/2020 M( 1 ) 118 ( 3 ) 03/12/2029 Common Stock 118 $ 0 107,383 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kelsey Stephen Michael
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
REDWOOD CITY, CA94063
See Remarks
Signatures
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey 08/31/2020
** Signature of Reporting Person Date
Explanation of Responses:
( 1 )Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
( 2 )The transaction was executed in multiple trades in prices ranging from $29.00 to $29.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
( 3 )One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:
President, Research and Development

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.